{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:35:01Z","timestamp":1792438501737,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016009","name":"Rising Tide Foundation for Clinical Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dld.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:21:12Z","timestamp":1764332472000},"page":"2470-2477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study"],"prefix":"10.1016","volume":"57","author":[{"given":"Carolina","family":"Sciortino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4207","authenticated-orcid":false,"given":"Federico","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giommoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Alessandra","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chiaramonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sottotetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-7751","authenticated-orcid":false,"given":"Antonia","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-5671","authenticated-orcid":false,"given":"Ilario Giovanni","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Murialdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Delliponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-7342","authenticated-orcid":false,"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Dell\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-3728","authenticated-orcid":false,"given":"Carlo","family":"Carnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0941-8547","authenticated-orcid":false,"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Rivizzigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mannavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Forti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Garajov\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Attademo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio Ken","family":"Garattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-7091","authenticated-orcid":false,"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.11.007_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2025.11.007_bib0003","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2025.11.007_bib0004","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.11.007_bib0008","doi-asserted-by":"crossref","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","article-title":"1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II\/III trial","volume":"34","author":"Ohba","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS479","article-title":"Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas","volume":"37","author":"Philip","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4004","article-title":"Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01","volume":"42","author":"Knox","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.dld.2025.11.007_bib0011","first-page":"11","article-title":"Comparative effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis","author":"Pusceddu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2025.11.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.45515","article-title":"Comparative outcomes of first-line chemotherapy for metastatic pancreatic cancer among the regimens used in Japan: a systematic review and network meta-analysis","volume":"5","author":"Takumoto","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2025.11.007_bib0013","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.dld.2025.11.007_bib0014","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.dld.2025.11.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and Gemcitabine with Nab-Paclitxel as Firs-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2025.11.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102502","article-title":"Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review","volume":"113","author":"Dayyani","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.dld.2025.11.007_bib0017","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.11.007_bib0018","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2022.40.16_suppl.4022","article-title":"Sequential nab-paclitaxel\/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial","volume":"40","author":"Carrato","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.dld.2025.11.007_bib0019","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/j.ejca.2014.09.015","article-title":"Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)","volume":"50","author":"Trouilloud","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.dld.2025.11.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100318","article-title":"Sequential first-line treatment with nab-paclitaxel\/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial","volume":"6","author":"Assenat","year":"2021","journal-title":"ESMO Open"},{"issue":"16","key":"10.1016\/j.dld.2025.11.007_bib0021","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2025.43.16_suppl.4184","article-title":"5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first-line treatment of metastatic pancreatic ductal adenocarcinoma: a randomized phase II comparative study (FUNGEMAX-PRODIGE 61)","volume":"43","author":"Taieb","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0022","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"Randon","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2024.42.3_suppl.605","volume":"42","author":"Dorman","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.dld.2025.11.007_bib0024","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.20.03329","article-title":"Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial","volume":"39","author":"Dahan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.11.007_bib0026","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","article-title":"Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting","volume":"13","author":"Stossel","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dld.2025.11.007_bib0027","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in Pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.dld.2025.11.007_bib0028","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/biom11111665","article-title":"LncRNAs: novel biomarkers for pancreatic cancer","volume":"11","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.dld.2025.11.007_bib0029","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-22-1272","article-title":"Correction: GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"28","author":"O'Kane","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2025.11.007_bib0030","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/annonc\/mdz181","article-title":"Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications","volume":"30","author":"Martens","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0031","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","article-title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma","volume":"32","author":"Nicolle","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0032","article-title":"Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the GemPred RNA signature: an ancillary study of the PRODIGE-24\/CCTG PA6 clinical trial","author":"Nicolle","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0033","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2022.11.035","article-title":"A transcriptomic-based tool to predict gemcitabine sensitivity in advanced pancreatic adenocarcinoma","volume":"164","author":"Fraunhoffer","year":"2023","journal-title":"Gastroenterology"},{"issue":"30","key":"10.1016\/j.dld.2025.11.007_bib0034","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.11.007_bib0035","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO-24-02210","article-title":"PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or Gemcitabine in locally advanced pancreatic carcinoma","volume":"43","author":"Ducreux","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.dld.2025.11.007_bib0036","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-023-11377-1","article-title":"Treatment sequences and prognostic\/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe","volume":"23","author":"Taieb","year":"2023","journal-title":"BMC Cancer"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582501206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582501206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:46:14Z","timestamp":1773863174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582501206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S159086582501206X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.11.007","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}